Document Type : Original Article
Authors
1
Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran
2
Department of Psychiatry, Kashan University of Medical Sciences, Kashan, Iran
3
Department of Addiction Studies, School of Medical and Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran
4
Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
10.48307/iahsj.2024.444695.1148
Abstract
Objectives: Methadone therapy, as one of the common methods of treating opioid dependence, is associated with some side effects. The purpose of this trial was to investigate curcuminoid supplementation on depression, anxiety, sleep quality and metabolic profiles of patients treated with methadone.
Methods: This is a clinical trial study. 60 participants (18-60 years) were included in the study according to the inclusion criteria, and finally the data of 47 people were confirmed for analysis. The participants were divided into two groups (randomly, control and intervention). Then their demographic information was collected. The intervention group received curcuminoid capsules every day and the control group received placebo capsules every day (12 weeks). Depression, sleep quality and anxiety (primary outcomes) among the participants were evaluated using Depression, Anxiety and Sleep Quality (in week 1 and week 12). 10 ml fasting blood was collected (week 1 and 12) from participants to evaluate blood sugar, lipid profile, oxidative stress biomarkers and inflammatory factors (secondary outcomes). At the end, the data were analyzed with statistical methods.
Results: No significant changes in the score of depression (BDI, P = 0.83), anxiety (BAI, P = 0.67) and sleep quality (PSQI, P = 0.96) in the 12th week compared to the beginning of the study. NO (P = 0.001), hs-CRP (P = 0.01), MDA (P = 0.004) and FPG (P = 0.03) factors in the intervention group were significantly decreased (12th week). No significant changes were observed in TG, VLDL-cholesterol, HDL-cholesterol, total cholesterol, LDL-cholesterol, TAC and GSH parameters between the two study groups in the 12th week (P > 0.05).
Conclusion: The results of our study indicated that curcuminoid supplementation can significantly reduce NO, hs-CRP, MDA and FPG levels among methadone users. It seems that curcuminoid supplementation can be considered as an adjunctive treatment to reduce some side effects of methadone. However, further studies in this field are suggested.
Keywords
Main Subjects
)